Ivosidenib

Contraindicated

Ivosidenib Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Ivosidenib Fostemsavir Rukobia Reduced temsavir exposure and possible loss of virologic response and increased risk of QT interval prolongation Details Ivosidenib Lefamulin Xenleta Reduced lefamulin exposure, reduced efficacy of lefamulin, an increased ivosidenib exposure, an increased risk of ivosidenib-relat... Details Ivosidenib Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Ivosidenib Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Ivosidenib Lurasidone Latuda Reduced lurasidone exposure Details Ivosidenib Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Ivosidenib Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Ivosidenib Abametapir Explained Increased exposure of CYP3A4 substrate Details Ivosidenib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Ivosidenib Sertraline Explained An increased risk of QT interval prolongation Details Ivosidenib Buprenorphine Belbuca Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Ivosidenib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Ivosidenib Simvastatin Flolipid Explained Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Ivosidenib Acalabrutinib Calquence Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Ivosidenib Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Ivosidenib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Ivosidenib Apixaban Eliquis Explained Reduced apixaban exposure Details Ivosidenib Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Ivosidenib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Ivosidenib Aripiprazole Injection Abilify Reduced ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongation Details Ivosidenib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Ivosidenib Asciminib Scemblix Reduced asciminib exposure, reduced efficacy of asciminib, an increased risk of ivosidenib exposure and an increased risk of ivosi... Details Ivosidenib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Ivosidenib Atogepant Qulipta Reduced atogepant exposure Details Ivosidenib Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Ivosidenib Azithromycin AzaSite An increased risk of QT interval prolongation Details Ivosidenib Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Ivosidenib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Ivosidenib Abiraterone Abirtega Reduced abiraterone exposure and reduced efficacy of abiraterone Details Ivosidenib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Ivosidenib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Ivosidenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Ivosidenib Anagrelide Agrylin An increased risk of QT interval prolongation Details Ivosidenib Avanafil Stendra Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Ivosidenib Bedaquiline Sirturo Reduced bedaquiline exposure, reduced efficacy of bedaquiline and an increased risk of QT interval prolongation Details Ivosidenib Bosutinib Bosulif Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Ivosidenib Brexpiprazole Rexulti Reduced brexpiprazole exposure Details Ivosidenib Budesonide Entocort Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Ivosidenib Budesonide Nasal Spray Rhinocort Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details